Status:
TERMINATED
Metformin in Non Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical research study is to learn if giving metformin in combination with radiation therapy is more effective than radiation therapy alone. In this study, participants will receive ...
Eligibility Criteria
Inclusion
- Patients with pathologic diagnosis of lung NSCLC or squamous cell carcinoma.
- Patients are to be treated with hypofractionated RT.
- Patient is not a surgical candidate due to medical comorbidities determined by a thoracic surgeon or patient refusal
- Patient plans to receive treatment at MD Anderson
- Patients must sign informed consent
- Patient must have adequate renal function within 30 days prior to registration, defined as serum creatinine within normal institutional limits or creatinine clearance at least 60 ml/min
Exclusion
- Patient has: random glucose \>200 mg/dl or is taking an oral hypoglycemic agent or insulin at the time of study entry
- Patient has a history of lactic acidosis, chronic kidney disease or a creatinine \>/= 1.2 mg/dl
- Women who are pregnant or breast feeding, as treatment involves unforeseeable risks to the participant, embryo, fetus, or nursing infant
- Patients with history of allergic reaction to metformin
Key Trial Info
Start Date :
February 20 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 5 2019
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT02285855
Start Date
February 20 2015
End Date
January 5 2019
Last Update
January 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030